Treatment of Patients With Major Depressive Disorder With MK0869 (0869-066)(COMPLETED)

A Worldwide, Multicenter, Double-Blind, Parallel, Active-Controlled, Long-Term Safety Study of MK0869 in Outpatients With Major Depressive Disorder

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00034983

Enrollment

900

Registered

2002-05-03

Start date

2001-10-29

Completion date

2003-12-29

Last updated

2017-04-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major Depressive Disorder

Brief summary

A clinical study to determine the efficacy and safety of an investigational medication (MK0869) in the treatment of depression

Detailed description

The duration of treatment is 1 year.

Interventions

DRUGaprepitant

DRUGComparator: paroxetine HCL

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Major Depressive Disorder

Design outcomes

Primary

Measure	Time frame
Long-term safety and tolerability.	Duration of treatment

Secondary

Measure	Time frame
Sexual dysfunction adverse experiences and gastrointestinal disturbance adverse experiences	Duration of treatment

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 5, 2026